Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/26/2870525/0/en/UPDATE-Ocugen-to-Present-on-Modifier-Gene-Therapy-Platform-at-Association-for-Research-in-Vision-and-Ophthalmology-2024-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/04/19/2866086/0/en/Ocugen-Announces-Dosing-Completion-of-Subjects-with-Geographic-Atrophy-in-Cohort-2-of-Phase-1-2-ArMaDa-Clinical-Trial-of-OCU410-A-Modifier-Gene-Therapy.html
https://www.globenewswire.com/news-release/2024/04/12/2862122/0/en/Ocugen-to-Participate-in-Fireside-Chat-at-the-Emerging-Growth-Virtual-Healthcare-Equity-Conference-Presented-by-Noble-Capital-Markets.html
https://www.globenewswire.com/news-release/2024/04/10/2860633/0/en/Ocugen-Inc-Announces-Positive-Scientific-Advice-from-the-European-Medicines-Agency-Related-to-the-Approval-Pathway-for-OCU400-Modifier-Gene-Therapy-for-Broad-Retinitis-Pigmentosa-I.html
https://www.globenewswire.com/news-release/2024/04/08/2859013/0/en/Ocugen-Inc-Announces-U-S-FDA-Clearance-of-IND-Amendment-to-Initiate-OCU400-Phase-3-Clinical-Trial-First-Gene-Therapy-to-Enter-Phase-3-with-a-Broad-Retinitis-Pigmentosa-Indication.html
https://www.globenewswire.com/news-release/2024/04/02/2855922/0/en/Ocugen-Provides-Business-Update-with-Certain-Financials-for-the-Year-Ending-2023.html
https://www.globenewswire.com/news-release/2024/04/01/2855565/0/en/Ocugen-Announces-Positive-Data-and-Safety-Monitoring-Board-Review-and-Initiation-of-Enrollment-in-Medium-Dose-for-OCU410ST-a-Modifier-Gene-Therapy-in-GARDian-Study-for-Stargardt-Di.html
https://www.globenewswire.com/news-release/2024/04/01/2855543/0/en/Ocugen-to-Host-Conference-Call-on-Tuesday-April-2-at-8-30-A-M-ET-to-Provide-Business-Update-with-Certain-Financials-for-the-Year-Ending-2023.html
https://www.globenewswire.com/news-release/2024/03/18/2847631/0/en/Ocugen-Inc-Appoints-Huma-Qamar-MD-MPH-as-Chief-Medical-Officer.html
https://www.globenewswire.com//news-release/2024/03/13/2845392/0/en/Ocugen-Inc-Announces-Dosing-Completion-of-Subjects-with-Geographic-Atrophy-in-Cohort-1-of-Phase-1-2-Clinical-Trial-Evaluating-the-Safety-and-Efficacy-of-OCU410.html